Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events

NT-300

Internally discovered and developed at Romark, NT-300 is an investigational new drug for treating influenza. NT-300 is administered orally, and laboratory studies have shown that it inhibits replication of influenza viruses by a new mechanism – acting at post-translational level by selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to endoglycosidase H digestion. By this mechanism, NT-300 impairs hemagglutinin intracellular trafficking and insertion into the host plasma membrane, a key step for correct assembly and exit of the virus from the host cell.

NT-300 is undergoing a global phase 3 clinical study in the treatment of uncomplicated influenza.